NordICC Trial Shows Modest Benefit of Screening Colonoscopy in Colorectal Cancer Prevention (asteriskmag.com)

• First RCT of screening colonoscopy: 18% incidence reduction, 10% mortality reduction (not significant).
• Only 42% of invitees participated; per-protocol analysis suggests larger but methodologically sensitive effects.
• Alternatives: fecal blood tests (9-22% mortality reduction) and sigmoidoscopy (26-30%).
• American gastroenterologists criticized study design; debate over optimal screening strategy.

"The NordICC trial, the first randomized controlled trial of screening colonoscopy, found an 18% reduction in colorectal cancer incidence but only a non-significant 10% reduction in mortality after 10 years in intention-to-screen analysis. Only 42% of invited participants underwent colonoscopy. American gastroenterologists criticized the trial due to low uptake, short follow-up, and potential lower skill of European endoscopists. Per-protocol analyses suggested larger benefits but were methodologically sensitive. The article discusses the debate and compares colonoscopy to sigmoidoscopy and fecal blood tests, concluding that screening is effective but the optimal method remains uncertain."